Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006788 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-02-03 | 2022-02-01 | VRTX | Sachdev Amit | EVP, Chief Patient Off | A - Grant | $0.00 | +29.6K | 41.7K | +245% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | A | A | 8,210 | $0.00 | 61,566 | D | — | — | (F3) Restricted stock unit award that vests in installments beginning on 02/24/2023. |
| 2 | Common | Common Stock | 2022-02-01 | A | A | 11,628 | $0.00 | 53,356 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. |
| 3 | Common | Common Stock | 2022-02-01 | A | A | 9,800 | $0.00 | 41,728 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. |